Information Provided By:
Fly News Breaks for March 8, 2018
CTMX
Mar 8, 2018 | 05:30 EDT
Cantor Fitzgerald analyst Mara Goldstein raised her price target for CytomX Therapeutics to $40 citing a roll forward into 2018 in her valuation. The analyst believes the company's Probody technology has the potential to improve on currently approved immuno-oncology agents as well as previously inaccessible drug targets for the treatment of cancer. She maintains an Overweight rating on the shares.
News For CTMX From the Last 2 Days
CTMX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.